Cancer Clinical Trials at MidMichigan Health

Clinical research studies serve to improve cancer treatment and ensure the highest possible level of patient care. Patients involved in research studies play an important role in advancing evidence-based medicine to future patients. There are tremendous advantages for patients having access to nationally sponsored clinical trials closer to home including treatment options that might otherwise not be available to them and by avoiding treatment delays and decreasing lengthy travel times. Patients are eligible to participate in research studies only after specific eligibility criteria have been met.

Current Cancer Clinical Trials at MidMichigan

Breast Cancer

  • SWOG S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer.
    e^3 Breast Cancer Study-Evaluating Everolimus with Endocrine Therapy.

    This study is for patients with invasive breast cancer that is hormone receptor-positive, HER2-negative, has completed surgery and chemotherapy, and is considered high-risk for the breast cancer to return.

    Purpose

    The purpose of this study is to test whether adding the drug everolimus (Afinitor) for one year to standard adjuvant endocrine therapy can delay the spread of cancer or recurrence of cancer in high-risk patients with Hormone Receptor-Positive, HER2-negative breast cancer.

    Patients will be followed for 10 years after registration into the study.

    • NCT: 01674140
  • ALLIANCE A011401: (Dr. Le) (BWEL TRIAL): Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer.
    • Currently enrolling participants.
    • NCT: 02750826
  • SWOG 1418:(Dr. Hurtubise): A randomized phase III trial to evaluate the efficacy and safety of MK-3475 as adjuvant therapy for triple receptor negative breast cancer with > 1cm residual invasive cancer or positive lymph nodes after neoadjuvant chemotherapy.
    • Currently enrolling participants.
    • NCT: 02954874

Lung Cancer

  • ALLIANCE A151216: (Dr. Regenbogen) (ALCHEMIST Trial): Adjuvant lung cancer enrichment marker identification and sequencing trial.
    • Currently enrolling participants.
    • NCT: 02194738
  • ALLIANCE A081105: (Dr. Regenbogen) (ALCHEMISTTrial): Randomized double blind placebo controlled study of Erlotinib or placebo in patients with completely resected epidermal growth factor mutant non-small cell lung cancer.
    • Currently enrolling participants.
    • NCT: 02193282
  • EA5142: (Dr. Regenbogen) (ALCHEMIST Trial): A randomized phase III study of Nivolumab after surgical resection and adjuvant chemotherapy in non-small cell lung cancers.
    • Currently enrolling participants.
    • NCT: 02595944
  • E4512:(Dr. Regenbogen) (ALCHEMIST Trial): A phase III double blind trial for surgically resected early stage non-small cell lung cancer: Crizotinib verses placebo for patients with tumors harboring the anaplastic lymphoma kinase (ALK) fusion protein (ALCHEMIST).
    • Currently enrolling participants.
    • NCT: 02201992

Multiple Myeloma

  • E1A11: (Dr. Regenbogen) (ENDURANCE Trial): A randomized phase III trial of Bortezomib, Lenalidomide, and Dexamethasone verses Carfilzomib, Lenalidomide, and Dexamethasone followed by limited or indefinite duration Lenalidomide maintenance in patients with newly diagnosed symptomatic multiple myeloma.
    • Currently enrolling participants.
    • NCT: 01863550
  • AMGEN 20170596: (Amgen sponsored –not NIH) (Dr. Akkad): An Open-Label Phase 2 Study of Carfilzomib Plus Dexamethasone To Assess Tolerability And Adherence In Subjects With Relapsed Or Refractory Multiple Myeloma At Us Community Oncology Centers.
    • Currently enrolling participants.
    • NCT: 03512353

Other

  • PRN1008-010: (Principia Sponsor- Not NIH) - Open 12/2018 (1 potential 01-2019): An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed ITP
    • Currently enrolling participants.
    • NCT: 03395210
  • Neulasta: AMGEN 20170758: (Amgen sponsored – Starting June) (Dr. Le): A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) Among Subjects with Non-myeloid Malignancies at High Risk for FN and Receiving Neulasta (pegfilgrastim) Onpro kit or Other Physician Choice Options for Prophylasis of FN.  

Related Locations